• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer.

作者信息

Travert Camille, Tomasini Pascale, Jeanson Arnaud, Greillier Laurent, Barlesi Fabrice

机构信息

Pneumology and Oncology Department, Centre Hospitalo-Universitaire de Montpellier, Montpellier University, Montpellier, France.

Department of Pneumology and Oncology, Arnaud de Villeneuve hospital, Montpellier, France.

出版信息

Transl Cancer Res. 2019 Nov;8(7):2514-2516. doi: 10.21037/tcr.2019.05.20.

DOI:10.21037/tcr.2019.05.20
PMID:35117007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8798806/
Abstract
摘要

相似文献

1
First-line pembrolizumab in programmed death ligand 1 positive non-small cell lung cancer.程序性死亡配体1阳性非小细胞肺癌的一线帕博利珠单抗治疗
Transl Cancer Res. 2019 Nov;8(7):2514-2516. doi: 10.21037/tcr.2019.05.20.
2
Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.西妥昔单抗联合化疗对比单纯化疗一线治疗晚期非小细胞肺癌的疗效和安全性：一项 Meta 分析
Value Health. 2022 Feb;25(2):203-214. doi: 10.1016/j.jval.2021.08.009. Epub 2021 Oct 16.
3
Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1.程序性死亡配体1表达≥50%的转移性非小细胞肺癌一线帕博利珠单抗单药治疗的长期真实世界结局
Front Oncol. 2022 Mar 25;12:834761. doi: 10.3389/fonc.2022.834761. eCollection 2022.
4
Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.比较程序性细胞死亡蛋白1（PD-1）和程序性细胞死亡配体1（PD-L1）抑制剂治疗晚期非小细胞肺癌的疗效和安全性：一项贝叶斯分析。
Transl Lung Cancer Res. 2020 Aug;9(4):1302-1323. doi: 10.21037/tlcr-20-192.
5
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗肿瘤表达程序性死亡配体1的转移性非小细胞肺癌患者。
Oncologist. 2016 May;21(5):643-50. doi: 10.1634/theoncologist.2015-0498. Epub 2016 Mar 29.
6
FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond.FDA 批准概要：帕博利珠单抗治疗转移性非小细胞肺癌：一线治疗及以上。
Oncologist. 2017 Nov;22(11):1392-1399. doi: 10.1634/theoncologist.2017-0078. Epub 2017 Aug 23.
7
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.帕博利珠单抗联合化疗对比单纯化疗用于无肿瘤 PD-L1 表达的晚期非小细胞肺癌患者：3 项随机对照研究的汇总分析。
Cancer. 2020 Nov 15;126(22):4867-4877. doi: 10.1002/cncr.33142. Epub 2020 Sep 11.
8
Pembrolizumab as the first-line monotherapy for non-small-cell lung cancer with a low programmed death ligand 1 threshold.帕博利珠单抗作为程序性死亡配体1低表达阈值的非小细胞肺癌的一线单药治疗方案。
J Cell Commun Signal. 2020 Mar;14(1):129-130. doi: 10.1007/s12079-020-00547-6. Epub 2020 Jan 13.
9
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies.帕博利珠单抗单药治疗 PD-L1 阳性晚期非小细胞肺癌老年患者的安全性和有效性：来自 KEYNOTE-010、KEYNOTE-024 和 KEYNOTE-042 研究的汇总分析。
Lung Cancer. 2019 Sep;135:188-195. doi: 10.1016/j.lungcan.2019.07.004. Epub 2019 Jul 8.
10
KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.KEYNOTE-025：帕博利珠单抗治疗既往接受治疗的 PD-L1 阳性晚期非小细胞肺癌日本患者的 1b 期研究。
Cancer Sci. 2019 Mar;110(3):1012-1020. doi: 10.1111/cas.13932. Epub 2019 Feb 16.

引用本文的文献

1
Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing.使用全外显子组测序评估多种癌症类型的肿瘤突变负荷。
Ann Transl Med. 2021 Sep;9(18):1437. doi: 10.21037/atm-21-4227.
2
Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.比较程序性细胞死亡蛋白1（PD-1）和程序性细胞死亡配体1（PD-L1）抑制剂治疗晚期非小细胞肺癌的疗效和安全性：一项贝叶斯分析。
Transl Lung Cancer Res. 2020 Aug;9(4):1302-1323. doi: 10.21037/tlcr-20-192.
3
Immunotherapy as a treatment for small cell lung cancer: a case report and brief review.免疫疗法治疗小细胞肺癌：一例报告及简要综述
Transl Lung Cancer Res. 2020 Apr;9(2):393-400. doi: 10.21037/tlcr.2020.03.20.

本文引用的文献

1
Real-world prevalence of programmed death ligand 1 expression in locally advanced or metastatic non-small-cell lung cancer: The global, multicenter EXPRESS study.真实世界中局部晚期或转移性非小细胞肺癌程序性死亡配体 1 表达的流行率：全球多中心 EXPRESS 研究。
Lung Cancer. 2019 Aug;134:174-179. doi: 10.1016/j.lungcan.2019.06.012. Epub 2019 Jun 12.
2
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
3
The clinical utility of tumor mutational burden in non-small cell lung cancer.肿瘤突变负荷在非小细胞肺癌中的临床应用价值
Transl Lung Cancer Res. 2018 Dec;7(6):639-646. doi: 10.21037/tlcr.2018.10.08.
4
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
5
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
6
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
7
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.纳武利尤单抗联合伊匹单抗治疗高肿瘤突变负荷肺癌。
N Engl J Med. 2018 May 31;378(22):2093-2104. doi: 10.1056/NEJMoa1801946. Epub 2018 Apr 16.
8
A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma.一项关于伊曲康唑与泼尼松龙治疗哮喘合并急性变应性支气管肺曲霉病的随机试验。
Chest. 2018 Mar;153(3):656-664. doi: 10.1016/j.chest.2018.01.005. Epub 2018 Jan 11.
9
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.一线纳武利尤单抗用于IV期或复发性非小细胞肺癌
N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.
10
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).阿特珠单抗作为程序性死亡配体1筛选的晚期非小细胞肺癌患者一线或后续治疗的II期试验（BIRCH）
J Clin Oncol. 2017 Aug 20;35(24):2781-2789. doi: 10.1200/JCO.2016.71.9476. Epub 2017 Jun 13.